Impacts of the Coronavirus 2019 Pandemic on Gastrointestinal Endoscopy Volume and Diagnosis of Gastric and Colorectal Cancers: A Population-Based Study.

The coronavirus disease 2019 (COVID-19) pandemic has caused a major disruption to our health care system. In response to the service demand surge and shortage of personal protective equipment, multiple professional societies have issued recommendations to defer elective endoscopic procedures except time-sensitive and emergency procedures.1, 2, 3 As yet, the real-life impact of this pragmatic service reduction is unknown. Here, we report the short-term impacts of the COVID-19 pandemic on the volume of gastrointestinal endoscopy and new diagnoses of gastric and colon cancers in Hong Kong and model the changes in cancer staging.

Methods

The first local COVID-19 case was reported on January 23, 2020, and through May 8, 2020, 1045 cases were reported. The total numbers of upper and lower endoscopy performed in all public hospitals in Hong Kong between October 1, 2019 and March 31, 2020 and from the same period in the preceding 3 years were retrieved from the Clinical Data Analysis and Reporting System of the Hong Kong Hospital Authority. Cancer diagnosis was verified by the Anatomic Pathology Database of the Clinical Data Analysis and Reporting System. , The autoregressive integrated moving average (ARIMA) model was used to predict the trend of patients newly diagnosed with gastric or colorectal cancers with the Buishand U test to determine the week of turning point of the sudden changes. A linear regression model was constructed to assess the relationship between the number of cancers diagnosed and the volume of endoscopy. The potential stage shifting of these cancers with delayed diagnosis was estimated by using a state-transition Markov model (Supplementary Material). The study was approved by the institutional review board of the University of Hong Kong and the Hong Kong West Cluster of Hospital Authority, Hong Kong (reference no. UW 20-279).

Results

The number of procedures performed and the number of cancers diagnosed in the study period are shown in Supplementary Table 1. The Buishand U test showed a turning point in the number of upper and lower endoscopies performed (P < .001) and the number of gastric and colorectal cancers diagnosed (P < .001) during the week of January 21–27, 2020, when the first local COVID-19 case was diagnosed. From that week onward, the mean number of upper and lower endoscopies performed per week dropped by 51.0% (from 1813 to 887; P < .001) and 58.8% (from 1190 to 491; P < .001), respectively. The mean gastric cancer and colorectal cancer diagnosed per week also fell by 46.2% (from 22.9 to 12.3; P < .001) and 37.0% (from 92.1 to 58; P < .001), respectively. Notably, the positive rates (per 1000 endoscopies) for gastric cancer remained static throughout these periods (11.8 to 13.9; P = .14) (Supplementary Table 1) but increased for colorectal cancer (75.6 to 118.2; P < .001).

Supplementary Table 1

Number of Endoscopic Procedures and Diagnoses in Hong Kong During the Study Period (October 1–March 31, 2016–2020)

Endoscopic procedures and diagnoses	Oct 2016–Mar 2017		Oct 2017–Mar 2018		Oct 2018–Mar 2019		Oct 2019–Mar 2020
							Before week of turning point (Jan 21–27)		After week of turning point (Jan 21–27)
	Whole period	Average per week	Whole period	Average per week	Whole period	Average per week	Whole period	Average per week	Whole period	Average per week
Upper endoscopy, n	46,129	1774.2	47,588	1830.3	48,302	1857.8	28,932	1808.3	8878	887.8
Lower endoscopy, n	31,142	1197.8	31,835	1224.4	29,522	1135.5	19,433	1214.6	4909	490.9
New gastric cancer, n	629	24.2	562	21.6	587	22.6	374	23.4	123	12.3
New colorectal cancer, n	2484	95.5	2388	91.8	2314	89.0	1469	91.8	580	58.0
Positive rate for gastric cancer per 1000 upper endoscopies	13.6	—	11.8	—	12.2	—	12.9	—	13.9	—
Positive rate for colorectal cancer per 1000 lower endoscopies	79.8	—	75.0	—	78.4	—	75.6	—	118.2	—

For gastric cancer, the ARIMA(0,1,1)(1,0,1)26 model with a 26-week cyclical pattern was fitted with data from previous years. The mean percent error values of the model were 2.5% and 3.5% for the training set and test set, respectively. For colorectal cancer, the mean percent error values of the ARIMA(0,0,1)(1,0,1)26 model were 2.8% and 3.3%, respectively. For the 10-week period starting from January 21, 2020, the predicted numbers of gastric cancers and colorectal cancers were higher than observed by 51.1%, (221; 95% confidence interval [CI], 136–357 vs 123; P < .01) and 32.9% (865; 95% CI, 668–1286 vs 580; P < .01), respectively (Figure 1 ). Based on the Markov model prediction, 4.6% of patients with gastric cancer and 6.4% of patients with colorectal cancer would have higher stage shifting at 6 months. In particular, the proportion of stage IV cancers increased (gastric: 30.5% to 32.4%; P < .01 and colorectal: 23.5% to 26.8%; P < .01).

Figure 1

(A, B) Actual vs predicted numbers (by ARIMA) of endoscopy and cancers diagnosed per week: (A) gastric cancer and (B) colorectal cancer. (C, D) Prediction of changes in cancer staging with various durations of COVID-19 outbreak in Hong Kong: (C) gastric cancer and (D) colorectal cancer. The shaded areas and error bars represent 95% CIs.

The linear regression model showed a linear relationship between the number of gastric cancers and upper endoscopy volume and between the number of colorectal cancers and lower endoscopy volume, both before (gastric: 0.68; 95% CI, 0.30–1.05; colorectal: 0.77; 95% CI, 0.54–0.94) and after the turning point (gastric: 0.42; 95% CI, 0.07–0.76; colorectal: 0.34; 95% CI, 0.05–0.37). If there is a further 20% reduction in current endoscopy volume, the corresponding mean numbers of gastric cancers and colorectal cancers diagnosed per week would fall by 54.1% (10.5 vs 22.9) and 41.1% (54.0 vs 91.7), respectively, from baseline. With a 20% greater reduction in endoscopy services, the predicted proportions of patients with gastric and colorectal cancer with stage upshifting were 5.3% (vs current 4.6%) and 7.2% (vs current 6.4%), respectively, at 6 months (Supplementary Figure 1).

Supplementary Figure 1

Predicted effects of various levels of endoscopy volume reduction on percentage of patients with cancer upstaging on diagnosis. (A) Gastric cancer. (B) Colorectal cancer.

Discussion

To our knowledge, this is the first study to quantify the disruption brought by the COVID-19 pandemic on the delivery of gastrointestinal endoscopy and its impacts on cancer diagnosis and staging at a population level. Although the volume of endoscopy was reduced by more than 50% in Hong Kong, the number of patients diagnosed with gastric and colorectal cancer dropped by 49.1% and 38.1%, respectively. Based on the ARIMA prediction and Markov model, we estimated that 4.6% and 6.4% of patients with gastric and colorectal cancer would have cancer stage upshifting at 6 months.

In a recent report from a single hospital in Shanghai, China, it was noted that the endoscopy volume dropped by 6.3 times during COVID-19. In another North American survey, 65% of centers were performing less than 10% of their usual volume. However, public hospitals in Hong Kong do not routinely perform screening endoscopy, and the potential impacts on delayed cancer diagnosis could be worse than in centers that primarily perform screening procedures.

Interestingly, we noted that the impact of service reduction on upper endoscopy was more critical than on lower colonoscopy because the positive rate for cancer by lower colonoscopy actually increased after the outbreak, suggesting that triage based on lower gastrointestinal symptoms is more reliable than upper gastrointestinal symptoms in arranging early endoscopy.

In conclusion, the COVID-19 outbreak has resulted in a substantial drop in endoscopy services in Hong Kong, which is associated with a significant delay in cancer diagnosis. The delay and subsequent cancer stage upshifting will be amplified if the COVID-19 pandemic lengthens further. Gradual resumption of nonemergency endoscopy services should be considered as early as feasible and practical, balancing the risks of delayed cancer diagnosis and the personal safety of patients and staff.